Keyphrases
Disease-modifying Antirheumatic Drugs (DMARDs)
100%
DANBIO Registry
100%
Inhibitor Treatment
100%
Radiographic Progression
100%
Clinical Practice
100%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
Rheumatoid Arthritis Patients
100%
Progression Rate
28%
Drug Treatment
28%
Disease Duration
14%
Current Smokers
14%
Anti-cyclic Citrullinated Peptide Antibody (anti-CCP)
14%
Conventional Radiographs
14%
Subsequent Therapy
14%
Sulfasalazine
14%
Patient Files
14%
Wrist
14%
Infliximab
14%
Prednisolone
14%
Etanercept
14%
Clinical Data
14%
Adalimumab
14%
Methotrexate
14%
IgA Rheumatoid Factor
14%
Nursing and Health Professions
Inflammatory Arthritis
100%
Rheumatoid Arthritis
100%
Tumor Necrosis Factor Inhibitor
100%
Clinical Practice
100%
Disease Modifying Antirheumatic Drug
100%
Adalimumab
14%
Drug Therapy
14%
Methotrexate
14%
Rheumatoid Factor
14%
Disease Duration
14%
Etanercept
14%
Prednisolone
14%
Infliximab
14%
Immunoglobulin M
14%
Tumor Necrosis Factor
14%
Medicine and Dentistry
Inflammatory Arthritis
100%
Rheumatoid Arthritis
100%
TNF Inhibitor
100%
Disease Modifying Antirheumatic Drug
100%
Drug Therapy
14%
Salazosulfapyridine
14%
Adalimumab
14%
Disease Duration
14%
Prednisolone
14%
Methotrexate
14%
Smoking
14%
Rheumatoid Factor
14%
Observational Study
14%
Infliximab
14%
Tumor Necrosis Factor
14%
Immunoglobulin M
14%
Etanercept
14%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Arthritis
100%
Rheumatoid Arthritis
100%
Disease Modifying Antirheumatic Drug
100%
Tumor Necrosis Factor Inhibitor
100%
Etanercept
14%
Disease Duration
14%
Tumor Necrosis Factor
14%
Prednisolone
14%
Rheumatoid Factor
14%
Sulfasalazine
14%
Immunoglobulin M
14%
Methotrexate
14%
Adalimumab
14%
Observational Study
14%
Infliximab
14%
Pharmacotherapy
14%
Immunology and Microbiology
Inflammatory Arthritis
100%
Disease-Modifying Antirheumatic Drug
100%
TNF Inhibitor
100%
Infliximab
14%
Prednisolone
14%
Adalimumab
14%
Peptides
14%
Etanercept
14%
Carpus
14%
Sulfasalazine
14%
Rheumatoid Factor
14%
Tumor Necrosis Factor
14%
Drug Therapy
14%
Immunoglobulin M
14%
Methotrexate
14%
Veterinary Science and Veterinary Medicine
Disease-Modifying Antirheumatic Drug
100%
Sulfasalazine
14%